Lyme Arthritis: Is Persistent Joint Pain Debris or Ongoing Infection?
Persistent joint pain after Lyme treatment may reflect more than immune debris.
New research found Borrelia burgdorferi peptidoglycan in joint fluid weeks after antibiotic therapy.
Whether this reflects inert debris or ongoing infection changes how treatment should proceed.
New research into Lyme arthritis is challenging long-standing assumptions about what causes persistent symptoms after treatment. For years, many clinicians believed that when patients continued to experience swollen joints after antibiotics, the inflammation was simply due to an overactive immune system reacting to leftover bacterial debris — not an ongoing infection.
But that explanation may not be the full story.
A recent study published in Science Translational Medicine examined the synovial fluid of patients with Lyme arthritis — often weeks or months after their initial diagnosis and antibiotic treatment. Researchers found peptidoglycan, a key structural molecule from the cell wall of Borrelia burgdorferi, still present in the joint fluid.
Peptidoglycan is known to trigger a strong immune response. Its presence has been proposed as a driver of continued inflammation in Lyme arthritis, even when live bacteria are no longer detectable. This raises a critical question: is this truly inert debris — or could it reflect persistent infection?
These findings are relevant to the broader question of persistent Lyme disease mechanisms and what drives ongoing illness after treatment.
The Current Assumption: Inflammation Without Infection
The prevailing view is that antibiotic-refractory Lyme arthritis results from immune activation triggered by residual bacterial material. This model suggests that after infection is cleared, fragments such as peptidoglycan continue to stimulate inflammation.
If this is the case, treatment may focus on immune modulation — such as NSAIDs, corticosteroids, or DMARDs — rather than additional antibiotics.
However, this explanation depends on an assumption that deserves closer examination: that the bacteria are truly gone.
The Limitation: Detecting Live Borrelia Is Difficult
In the study, live Borrelia organisms were not detected in joint fluid. However, absence of detectable bacteria is not evidence of absence.
Detecting Borrelia in synovial fluid or tissue is inherently challenging. The organism may exist in low numbers, within protected niches, or in forms that evade conventional PCR or culture methods.
That means peptidoglycan seen in joint fluid could, in some cases, reflect ongoing bacterial turnover — not just sterile remnants. This would imply that in at least a subset of patients, the infection persists despite antibiotic treatment.
Such cases could still benefit from additional or combination antibiotic therapy — not just anti-inflammatory or immunosuppressive approaches. These challenges parallel the broader limitations discussed in Lyme disease misdiagnosis.
Clinical Implications: Why This Distinction Matters
Understanding whether inflammation reflects persistent infection or post-infectious immune activation is critical for treatment decisions.
If infection persists, suppressing the immune system without addressing the underlying cause may delay recovery or worsen outcomes. If inflammation is truly immune-driven, unnecessary antibiotic use may expose patients to risk without benefit.
Both scenarios likely exist in different patients — which may explain the wide variability in treatment outcomes. Some improve with a second course of antibiotics. Others need immune-focused therapies. Without a reliable test to distinguish between these cases, treatment decisions remain complex and often individualized.
This variability is consistent with patterns described in post-treatment Lyme disease syndrome (PTLDS), where persistent symptoms after treatment may reflect different underlying mechanisms in different patients.
In my practice, I have seen patients whose persistent joint symptoms were attributed to immune debris who improved significantly with additional antibiotic treatment. These cases raise serious questions about whether the debris explanation is being applied too broadly — and whether some patients are being steered away from treatment that could help them.
A More Nuanced Understanding
The identification of peptidoglycan advances understanding of Lyme arthritis — but also highlights ongoing uncertainty. Treating all persistent symptoms as post-infectious may leave some patients undertreated. Treating all patients with extended antibiotics may lead to overtreatment.
A more individualized, evidence-informed approach is needed — one that acknowledges the limitations of current testing, the biology of bacterial persistence, and the diverse experiences of patients.
Until we can reliably tell whether inflammation means debris or active disease, the question of lingering infection remains open — and clinically critical.
Frequently Asked Questions
Can Lyme disease cause persistent joint pain after treatment?
Yes. Some patients experience ongoing joint swelling and pain even after completing antibiotic therapy. This is sometimes called antibiotic-refractory Lyme arthritis and may reflect immune activation, persistent infection, or both.
What is peptidoglycan and why does it matter in Lyme arthritis?
Peptidoglycan is a structural molecule from the Borrelia burgdorferi cell wall. Its presence in joint fluid after treatment suggests that bacterial material persists and may continue to drive inflammation — raising questions about whether infection is truly cleared.
Does peptidoglycan prove the infection is still active?
Not definitively. It may represent leftover debris or ongoing bacterial turnover. Current testing cannot reliably distinguish between these possibilities, which is why individualized clinical evaluation remains essential.
Should patients with persistent Lyme joint pain receive more antibiotics?
This depends on the individual clinical picture. Some patients improve with additional antibiotic therapy while others respond better to immune-directed treatments. Without reliable tools to distinguish between mechanisms, treatment decisions require careful clinical judgment.
Clinical Takeaway
Peptidoglycan from Borrelia burgdorferi can persist in joint fluid after treatment and may drive ongoing inflammation. Whether this reflects inert debris or persistent infection remains uncertain — and that uncertainty has direct implications for how patients are treated.
Suppressing immune activity without considering whether infection persists may leave some patients undertreated. Applying extended antibiotic therapy without clinical justification carries its own risks. Both scenarios exist, and both deserve consideration in patients with persistent joint symptoms after Lyme treatment.
Until reliable tools exist to distinguish post-infectious inflammation from persistent active infection, careful individualized evaluation — not a one-size-fits-all protocol — remains the most defensible approach.
Related Articles
- Persistent Lyme Disease Mechanisms
- Post-Treatment Lyme Disease Syndrome (PTLDS)
- Persistent Lyme Infection or Inflammatory Immune Response?
- Knee Pain and Lyme Disease
- Lyme Disease Misdiagnosis
References
- Jutras BL, Lochhead RB, Kloos ZA, et al. Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis. Proc Natl Acad Sci. 2019;116(27):13498–13507.
- Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am. 2015;29(2):269–280.
- Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987;107(5):725–731.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
Thank you very much for publishing this research.
I look forward to more!